282 related articles for article (PubMed ID: 32853175)
1. ATP synthase and Alzheimer's disease: putting a spin on the mitochondrial hypothesis.
Ebanks B; Ingram TL; Chakrabarti L
Aging (Albany NY); 2020 Aug; 12(16):16647-16662. PubMed ID: 32853175
[TBL] [Abstract][Full Text] [Related]
2. ATP Synthase and Mitochondrial Bioenergetics Dysfunction in Alzheimer's Disease.
Patro S; Ratna S; Yamamoto HA; Ebenezer AT; Ferguson DS; Kaur A; McIntyre BC; Snow R; Solesio ME
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681851
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease.
Bosetti F; Brizzi F; Barogi S; Mancuso M; Siciliano G; Tendi EA; Murri L; Rapoport SI; Solaini G
Neurobiol Aging; 2002; 23(3):371-6. PubMed ID: 11959398
[TBL] [Abstract][Full Text] [Related]
4. Association of ATP synthase alpha-chain with neurofibrillary degeneration in Alzheimer's disease.
Sergeant N; Wattez A; Galván-valencia M; Ghestem A; David JP; Lemoine J; Sautiére PE; Dachary J; Mazat JP; Michalski JC; Velours J; Mena-López R; Delacourte A
Neuroscience; 2003; 117(2):293-303. PubMed ID: 12614671
[TBL] [Abstract][Full Text] [Related]
5. Cyclical mitochondrial deltapsiM fluctuations linked to electron transport, F0F1 ATP-synthase and mitochondrial Na+/Ca+2 exchange are reduced in Alzheimer's disease cybrids.
Thiffault C; Bennett JP
Mitochondrion; 2005 Apr; 5(2):109-19. PubMed ID: 16050977
[TBL] [Abstract][Full Text] [Related]
6. Cyclophilin D Promotes Brain Mitochondrial F1FO ATP Synthase Dysfunction in Aging Mice.
Gauba E; Guo L; Du H
J Alzheimers Dis; 2017; 55(4):1351-1362. PubMed ID: 27834780
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial ATP-synthase in the entorhinal cortex is a target of oxidative stress at stages I/II of Alzheimer's disease pathology.
Terni B; Boada J; Portero-Otin M; Pamplona R; Ferrer I
Brain Pathol; 2010 Jan; 20(1):222-33. PubMed ID: 19298596
[TBL] [Abstract][Full Text] [Related]
8. Deregulation of mitochondrial F1FO-ATP synthase via OSCP in Alzheimer's disease.
Beck SJ; Guo L; Phensy A; Tian J; Wang L; Tandon N; Gauba E; Lu L; Pascual JM; Kroener S; Du H
Nat Commun; 2016 May; 7():11483. PubMed ID: 27151236
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of Mitochondrial Dysfunction in Alzheimer's Disease.
Cadonic C; Sabbir MG; Albensi BC
Mol Neurobiol; 2016 Nov; 53(9):6078-6090. PubMed ID: 26537901
[TBL] [Abstract][Full Text] [Related]
10. Cyclophilin D deficiency attenuates mitochondrial F1Fo ATP synthase dysfunction via OSCP in Alzheimer's disease.
Gauba E; Chen H; Guo L; Du H
Neurobiol Dis; 2019 Jan; 121():138-147. PubMed ID: 30266287
[TBL] [Abstract][Full Text] [Related]
11. Protective effects of a natural product, curcumin, against amyloid β induced mitochondrial and synaptic toxicities in Alzheimer's disease.
Reddy PH; Manczak M; Yin X; Grady MC; Mitchell A; Kandimalla R; Kuruva CS
J Investig Med; 2016 Dec; 64(8):1220-1234. PubMed ID: 27521081
[TBL] [Abstract][Full Text] [Related]
12. Decreased levels of complex III core protein 1 and complex V beta chain in brains from patients with Alzheimer's disease and Down syndrome.
Kim SH; Vlkolinsky R; Cairns N; Lubec G
Cell Mol Life Sci; 2000 Nov; 57(12):1810-6. PubMed ID: 11130185
[TBL] [Abstract][Full Text] [Related]
13. ATP Synthase, a Target for Dementia and Aging?
Larrick JW; Larrick JW; Mendelsohn AR
Rejuvenation Res; 2018 Feb; 21(1):61-66. PubMed ID: 29461942
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective Effects of Icariin on Brain Metabolism, Mitochondrial Functions, and Cognition in Triple-Transgenic Alzheimer's Disease Mice.
Chen YJ; Zheng HY; Huang XX; Han SX; Zhang DS; Ni JZ; He XY
CNS Neurosci Ther; 2016 Jan; 22(1):63-73. PubMed ID: 26584824
[TBL] [Abstract][Full Text] [Related]
15. Deciphering the 'Elixir of Life': Dynamic Perspectives into the Allosteric Modulation of Mitochondrial ATP Synthase by J147, a Novel Drug in the Treatment of Alzheimer's Disease.
Emmanuel IA; Olotu FA; Agoni C; Soliman MES
Chem Biodivers; 2019 Jun; 16(6):e1900085. PubMed ID: 30990952
[TBL] [Abstract][Full Text] [Related]
16. Abnormal levels of prohibitin and ATP synthase in the substantia nigra and frontal cortex in Parkinson's disease.
Ferrer I; Perez E; Dalfó E; Barrachina M
Neurosci Lett; 2007 Mar; 415(3):205-9. PubMed ID: 17284347
[TBL] [Abstract][Full Text] [Related]
17. Dysfunction of mitochondria: Implications for Alzheimer's disease.
Albensi BC
Int Rev Neurobiol; 2019; 145():13-27. PubMed ID: 31208523
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial dysfunction in Alzheimer's disease: Therapeutic implications of lithium.
Singulani MP; De Paula VJR; Forlenza OV
Neurosci Lett; 2021 Aug; 760():136078. PubMed ID: 34161823
[TBL] [Abstract][Full Text] [Related]
19. A Newly Synthesized Rhamnoside Derivative Alleviates Alzheimer's Amyloid-
Li Y; Lu J; Cao X; Zhao H; Gao L; Xia P; Pei G
Oxid Med Cell Longev; 2020; 2020():7698560. PubMed ID: 32104538
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: implications for early mitochondrial dysfunction and oxidative damage.
Manczak M; Park BS; Jung Y; Reddy PH
Neuromolecular Med; 2004; 5(2):147-62. PubMed ID: 15075441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
